Thermo Fisher Scientific is acquiring Mesa Biotech for about $450 million in cash, and will pay an additional $100 million in cash after certain milestones are hit.

Affinivax Inc., a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS (Multiple Antigen Presenting System) platform, announced the closing of a $226 million Series C financing.

The world is caught in a perfect storm of rising rates of chronic disease, persistent infectious diseases and public health failures that have fuelled deaths in the Covid-19 pandemic, according to a major global study of human health.

Hexagon Bio, a California-based biotechnology company turning nature’s DNA into medicines for cancers and infectious diseases with unmet needs, will move into clinical research with $47 million in Series A financing.  

Point-of-care testing is a critical tool in the battle against Covid-19, and researchers in Indiana are working around the clock to deliver rapid tests with high specificity.

This panel discussion will feature the top minds in infectious diseases, virology and vaccinology, who will give participants a breakdown of the top vaccine candidates and the latest information on clinical trials.

GlaxoSmithKline and Germany-based CureVac forged a strategic collaboration worth nearly $1 billion to develop up to five messenger RNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens.

Glympse Bio secured $46.7 million in a Series B fundraising round that will be used to support continued development of the company’s novel biosensor platform in fibrotic diseases such as non-alcoholic steatohepatitis (NASH), oncology and infectious diseases.

The National Institute of Allergy & Infectious Diseases (NIAID) has founded a new clinical trials network focused on enrolling volunteers in clinical trials for COVID-19 vaccines and monoclonal antibodies.

Sanofi Pasteur and Lexington, Massachusetts-based Translate Bio announced the expansion of an existing collaboration to develop mRNA vaccines for infectious diseases.